Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 316 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

NCT03198507
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
RHB-105, Active Comparator
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
55
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, KarX-EC, Placebo, Omeprazole
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
19 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00001337
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions
Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose
Drug · Biological · Diagnostic Test + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 17, 2026, 4:40 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

NCT00222079
View directory record Official record
Conditions
Gastro-esophageal Reflux
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
Douglas Trask
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

NCT04128787
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG881 Formulation 1, AG881 Formulation 2, Omeprazole
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain (Phase 2)

NCT02986334
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Omeprazole, Placebo
Drug
Lead sponsor
Apkar Apkarian
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

NCT07223671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Repotrectinib, Metformin, Digoxin, Rosuvastatin, Bupropion, Flurbiprofen, Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 4:40 AM EDT
Withdrawn Early Phase 1 Interventional

CYP2C19 Genotype Predictor of Gastric Acid Suppression

NCT01824199
View directory record Official record
Conditions
Esophagitis
Interventions
Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

NCT02226783
View directory record Official record
Conditions
Healthy Volunteers Food Interaction Study
Interventions
AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00961350
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PA32540, EC Aspirin 325
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 3 Interventional

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241540
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04562116
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab, CYP 450 Substrates
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

NCT01539655
View directory record Official record
Conditions
Medullary Thyroid Cancer
Interventions
vandetanib, omeprazole, ranitidine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 17, 2026, 4:40 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

NCT01723059
View directory record Official record
Conditions
Helicobacter Infection
Interventions
Standard Triple Therapy, Sequential Therapy
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

NCT04525664
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
Clarithromycin 500mg, Amoxicillin 1000 MG, Omeprazole 40 MG, Omeprazole 20 MG Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

NCT01358383
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
naproxen, esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Results available

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

NCT01093755
View directory record Official record
Conditions
Inflammation, Barrett's Esophagus
Interventions
dexlansoprazole, Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 17, 2026, 4:40 AM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Prilosec Bioequivalence Study in Healthy Volunteers

NCT01921920
View directory record Official record
Conditions
Bioequivalence, AUC, Cmax, Pharmacokinetics
Interventions
Omeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 17, 2026, 4:40 AM EDT